Efficacy of vitamin D supplement and topical benzoyl peroxide in mild to moderate acne

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210616002

Enrollment

Registered

2021-06-16

Start date

2021-06-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate acne Vitamin D, acne vulgaris

Interventions

44 subjects of acne patients will be randomly assigned to one of two groups. Group 1 : 22 subjects receive Topical 2.5% Benzoyl peroxide apply 5-15 minutes, then wash off twice daily and oral ergoca

Active Comparator Drug,Placebo Comparator Drug

Oral Ergocalciferol 40000 unit weekly with 2.5%benzoyl peroxide twice daily,oral placebo weekly with 2.5%benzoyl peroxide twice daily

Eligibility

Sex/Gender

All

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Patient who had mild to moderate acne according to global acne grading system

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Patient who has history of multiple sclerosis, systemic lupus erythema, sarcoidosis, diabetes mellitus, rheumatoid arthritis, renal failure, any type of liver disease or inflammatory bowel disease 3. Patient who has history or clinically suspected of polycystic ovary syndrome including ovulatory dysfunction 4. Use of topical medication (immunosuppressant, retinoid, benzoyl peroxide, topical antibiotics, corticosteroids and dermocosmetics) on the face within the last 2 weeks 5. Receiving systemic medication for acne treatment, vitamin D supplement, systemic steroids within the last 4 weeks 6. Receiving hormonal supplement within the last 3 months 7. Possible allergy to topical benzoyl peroxide or oral ergocalciferol.

Design outcomes

Primary

Measure	Time frame
Change in total acne lesion counts 12 weeks Total lesion counts	—

Secondary

Measure	Time frame
Change in inflammatory acne lesion counts 12 weeks Inflammatory acne lesion counts,Change in Non - inflammatory acne lesion counts 12 weeks Non - inflammatory acne lesion counts,Change in Investigator Global Assessment (IGA) 12 weeks Investigator Global Assessment (IGA),Change in Global Acne Grading Scale (GAGS) 12 weeks Global Acne Grading Scale (GAGS),Change in Dermatology Life Quality Index (DLQI) 12 weeks Dermatology Life Quality Index (DLQI)	—

Measure

Time frame

Change in inflammatory acne lesion counts 12 weeks Inflammatory acne lesion counts,Change in Non - inflammatory acne lesion counts 12 weeks Non - inflammatory acne lesion counts,Change in Investigator Global Assessment (IGA) 12 weeks Investigator Global Assessment (IGA),Change in Global Acne Grading Scale (GAGS) 12 weeks Global Acne Grading Scale (GAGS),Change in Dermatology Life Quality Index (DLQI) 12 weeks Dermatology Life Quality Index (DLQI)

—

Countries

Thailand

Contacts

Public ContactPremjit Juntongjin

Thammasat

premjitvp@yahoo.com025644444

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026